DrugPatentWatch Database Preview
Patents Expiring in 2026
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | GRANULE;ORAL | 211358-002 | Aug 7, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR | |||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-001 | Feb 16, 2018 | RX | Yes | No | Start Trial | Start Trial | TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION | ||||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-003 | Feb 16, 2018 | RX | Yes | No | Start Trial | Start Trial | TREATMENT OF MARGINAL ZONE LYMPHOMA | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
